Edition:
United States

Melinta Therapeutics, Inc. (MLNT.OQ)

MLNT.OQ on NASDAQ Stock Exchange Global Select Market

4.12USD
11:35am EDT
Change (% chg)

$-0.08 (-1.79%)
Prev Close
$4.20
Open
$4.15
Day's High
$4.20
Day's Low
$4.10
Volume
34,555
Avg. Vol
103,851
52-wk High
$18.15
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

Melinta Therapeutics Q4 Loss Per Share $1.48
Tuesday, 13 Mar 2018 07:00am EDT 

March 13 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.48.Q4 EARNINGS PER SHARE VIEW $-0.76 -- THOMSON REUTERS I/B/E/S.MELINTA THERAPEUTICS - ‍AS OF DEC 31, 2017, HAD CASH AND CASH EQUIVALENTS OF $128.4 MILLION​.  Full Article

Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application For Delafloxacin In Europe
Thursday, 8 Mar 2018 07:00am EST 

March 8 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS PARTNER, MENARINI GROUP, SUBMITS MARKETING AUTHORIZATION APPLICATION FOR DELAFLOXACIN IN EUROPE.MELINTA THERAPEUTICS, INC. - MENARINI GROUP SUBMITTED MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR DELAFLOXACIN.  Full Article

Melinta Therapeutics Files For Resale Of Up To 3.3 Mln Shares By Selling Stockholder
Tuesday, 9 Jan 2018 05:31pm EST 

Jan 9 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING.  Full Article

Deerfield Management Reports 10 Pct Passive Stake In Melinta Therapeutics
Tuesday, 9 Jan 2018 04:45pm EST 

Jan 9 (Reuters) - Melinta Therapeutics Inc ::DEERFIELD MANAGEMENT COMPANY LP REPORTS A 10 PCT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN 5 - SEC FILING.  Full Article

Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company
Wednesday, 29 Nov 2017 07:00am EST 

Nov 29 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY.  Full Article

Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics
Wednesday, 29 Nov 2017 07:00am EST 

Nov 29 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS.MEDICINES - TO SELL INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS FOR $270 MILLION IN UPFRONT CONSIDERATION AND GUARANTEED PAYMENTS.MEDICINES - DEAL INCLUDES TIERED ROYALTY PAYMENTS OF 5% TO 25% ON WORLDWIDE NET SALES OF VABOMERE, ORBACTIV AND MINOCIN IV, AMONG OTHER THINGS.MEDICINES CO - MELINTA TO PAY DEAL CONSIDERATION, INCLUDING $165 MILLION IN CASH, PAID AT CLOSING, MELINTA SHARES WITH A MARKET OF $55 MILLION, AMONG OTHERS.MEDICINES CO - ‍CONCURRENT WITH EXECUTION OF DEAL, CO RECEIVED BINDING COMMITMENT FROM DEERFIELD MANAGEMENT AFFILIATE.MEDICINES CO - DEERFIELD MANAGEMENT ‍AFFILIATE COMMITTED TO PROVIDE FINANCING TO MELINTA IN CONNECTION WITH DEAL,TO PROVIDE A $100 MILLION CREDIT FACILITY​.  Full Article

‍Melinta Therapeutics, Cempra name Daniel Wechsler as CEO of combined company
Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Cempra Inc :‍Melinta Therapeutics says co, Cempra announced that their selection committee selected Dan Wechsler to be president and CEO of combined company​.  Full Article

Cempra and Melinta announce expiration of Hart-Scott-Rodino waiting period for proposed merger
Thursday, 28 Sep 2017 04:15pm EDT 

Sept 28 (Reuters) - Cempra Inc :Cempra and Melinta announce expiration of Hart-Scott-Rodino waiting period for proposed merger.Cempra Inc - ‍both companies expect transaction to be completed in Q4 of 2017​.Cempra inc - ‍waiting period under Hart-Scott-Rodino with respect to Melinta's pending merger with a subsidiary of Cempra has now expired​.  Full Article

Cempra and Melinta announce merger to form leading, vertically integrated commercial-stage anti-infectives company
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Cempra Inc :Cempra and Melinta announce merger to form leading, vertically integrated commercial-stage anti-infectives company.Cempra Inc - ‍On a pro forma basis, current Cempra shareholders will own approximately 48 percent of combined company​.Says ‍on a pro forma basis, current Melinta shareholders will own approximately 52 percent of combined company​.Cempra Inc - ‍Board of directors of combined co will have 9 seats, with 4 appointed by Cempra, 4 appointed by Melinta, together with newly appointed CEO​.Says ‍combined company, which will be named Melinta Therapeutics​.Cempra Inc - ‍melinta will designate chairman of combined company board​.  Full Article

Cempra reports Q2 loss per share $0.23
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Cempra Inc :Cempra provides corporate update and reports second quarter 2017 financial results.Q2 loss per share $0.23.Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Cempra Inc - ‍In Q1 of 2017, met with FDA to discuss solithromycin complete response letter (CRL)​.Cempra Inc - ‍FDA reiterated their request for additional clinical safety data prior to approval for solithromycin​.Cempra Inc - ‍FDA has stated that phase 3 trials provided evidence that oral and intravenous (IV) solithromycin are effective for treatment of CABP​.Cempra Inc - ‍FDA has not requested further efficacy data to support co's response to CRL for solithromycin​.Cempra Inc - ‍Continue to advance manufacturing activities for solithromycin at Uquifa.Cempra - Engaged with potential government and industry partners to identify non-dilutive funding to support execution of solithromycin study ​.Cempra Inc - ‍Expect to reduce second half 2017 expenses by more than 70 percent compared to second half of 2016​.  Full Article